MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Description

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Conditions

Prostate Cancer, Prostate Adenocarcinoma, Prostate Neoplasm

Talk to us

Study Overview

On this page

Study Details

Study overview

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Condition
Prostate Cancer
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Chicago Medicine Comprehensive Cancer Center, Chicago, Illinois, United States, 60637

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.
  • * Voluntary written informed consent before the MRI examination.
  • * Subjects incapable of giving informed written consent.
  • * Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;
  • * Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.
  • * Prisoners.
  • * Minor children (under the age of 18 years old).
  • * Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

MALE

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Chicago,

Aytekin Oto, MD, STUDY_CHAIR, University of Chicago Medicine Comprehensive Cancer Center

Study Record Dates

2026-05-01